Why Assembly Biosciences Stock Is Trading Lower Today

Assembly Biosciences ASMB shares are trading lower on Friday after the company announced its HBV field core inhibitor combination study did not achieve endpoints.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein.

Assembly Biosciences shares were trading down 68.43% at $5.02 on Friday. The stock has a 52-week high of $27.84 and a 52-week low of $4.88.